-
2
-
-
0033006836
-
Cancer statistics, 1999
-
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8.
-
(1999)
CA Cancer J Clin
, vol.49
, pp. 8
-
-
Landis, S.H.1
Murray, T.2
Bolden, S.3
Wingo, P.A.4
-
3
-
-
0003017356
-
Cancer of the stomach
-
De Vita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins;
-
Karpeh MS, Kelsen DP, Tepper JE. Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA. 'Cancer. Priciples and practice of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1092.
-
(2001)
'Cancer. Priciples and Practice of Oncology, 6th Ed.
, pp. 1092
-
-
Karpeh, M.S.1
Kelsen, D.P.2
Tepper, J.E.3
-
5
-
-
0027467778
-
Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere. Reversibility, ligand stoichiometry, and competition
-
Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere. Reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-55.
-
(1993)
Biochemistry
, vol.32
, pp. 2747-2755
-
-
Diaz, J.F.1
Andreu, J.M.2
-
6
-
-
0000297058
-
Taxol stabilized microtubules in mouse fibroblast cells
-
Schiff PB, Horwitz SB. Taxol stabilized microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77: 1561-5.
-
(1980)
Proc Natl Acad Sci USA
, vol.77
, pp. 1561-1565
-
-
Schiff, P.B.1
Horwitz, S.B.2
-
7
-
-
0029996299
-
Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancer in vitro and in vivo
-
Tanaka M, Obata T, Sasaki T, et al. Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancer in vitro and in vivo. Eur J Cancer 1996; 32A: 226-30.
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 226-230
-
-
Tanaka, M.1
Obata, T.2
Sasaki, T.3
-
8
-
-
0033396484
-
Taxotere activates transcription factor AP-1 in association with apoptotic cell death in gastric cancer cell lines
-
Kim R, Ohi Y, Inoue H, Toge T. Taxotere activates transcription factor AP-1 in association with apoptotic cell death in gastric cancer cell lines. Anticancer Res 1999; 19: 5399-405.
-
(1999)
Anticancer Res
, vol.19
, pp. 5399-5405
-
-
Kim, R.1
Ohi, Y.2
Inoue, H.3
Toge, T.4
-
9
-
-
0028487470
-
Docetaxel (Taxotere) in advanced gastric cancer. Results of a phase II clinical trial
-
Sulkes A, Smythe J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer. Results of a phase II clinical trial. Br J Cancer 1994; 70: 183-4.
-
(1994)
Br J Cancer
, vol.70
, pp. 183-184
-
-
Sulkes, A.1
Smythe, J.2
Sessa, C.3
-
10
-
-
0030451795
-
Phase II trial of docetaxel in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy. The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293
-
Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy. The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87-93.
-
(1996)
Med Oncol
, vol.13
, pp. 87-93
-
-
Einzig, A.I.1
Neuberg, D.2
Remick, S.C.3
-
11
-
-
0345292180
-
Docetaxel (Taxotere) as a salvage chemotherapy in patients with advanced gastric cancer. A phase II study of the Southern Italian Oncology Group (GOIM)
-
25th meeting: 296 abstract
-
Giuliani F, Gebbia V, De Vita F, et al. Docetaxel (Taxotere) as a salvage chemotherapy in patients with advanced gastric cancer. A phase II study of the Southern Italian Oncology Group (GOIM). Proc Eur Soc Med Oncol 2000; 25th meeting: 296 abstract.
-
(2000)
Proc Eur Soc Med Oncol
-
-
Giuliani, F.1
Gebbia, V.2
De Vita, F.3
-
12
-
-
0034449134
-
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor: A phase II trial
-
Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor: a phase II trial. Am J Clin Oncol 2000; 23: 341-4.
-
(2000)
Am J Clin Oncol
, vol.23
, pp. 341-344
-
-
Mavroudis, D.1
Kourousis, C.2
Androulakis, N.3
-
13
-
-
0000149185
-
Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer
-
35th annual meeting: 1163 abstract
-
Vanhoefer U, Wilke H, Harstrick A, et al. Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer. Proc Am Soc Clin Oncol 1999; 35th annual meeting: 1163 abstract.
-
(1999)
Proc Am Soc Clin Oncol
-
-
Vanhoefer, U.1
Wilke, H.2
Harstrick, A.3
-
14
-
-
0036654749
-
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: A phase II trial
-
Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002; 32: 248-54.
-
(2002)
Jpn J Clin Oncol
, vol.32
, pp. 248-254
-
-
Bang, Y.J.1
Kang, W.K.2
Kang, Y.K.3
-
15
-
-
18144450345
-
Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese Cooperative Study Group trial (group A)
-
Taguchi T, Sakata Y, Kanamaru R, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 1998; 25: 1915-24.
-
(1998)
Gan to Kagaku Ryoho
, vol.25
, pp. 1915-1924
-
-
Taguchi, T.1
Sakata, Y.2
Kanamaru, R.3
-
16
-
-
0033758526
-
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
-
Graziano F, Catalino V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11: 1263-6.
-
(2000)
Ann Oncol
, vol.11
, pp. 1263-1266
-
-
Graziano, F.1
Catalino, V.2
Baldelli, A.M.3
-
17
-
-
17744389781
-
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer
-
Cascinu S, Graziano F, Barni S, et al. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 2001; 84: 470-4.
-
(2001)
Br J Cancer
, vol.84
, pp. 470-474
-
-
Cascinu, S.1
Graziano, F.2
Barni, S.3
-
18
-
-
0027944838
-
Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro
-
Hill BT, Whelan RD, Shellard SA, et al. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994; 12: 169-82.
-
(1994)
Invest New Drugs
, vol.12
, pp. 169-182
-
-
Hill, B.T.1
Whelan, R.D.2
Shellard, S.A.3
-
19
-
-
0037295092
-
Chemotherapy in gastric cancer: A never ending saga
-
Roth AD. Chemotherapy in gastric cancer: a never ending saga. Ann Oncol 2003; 14: 175-7.
-
(2003)
Ann Oncol
, vol.14
, pp. 175-177
-
-
Roth, A.D.1
-
20
-
-
0034449134
-
Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor: A phase II trial
-
Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor: a phase II trial. Am J Clin Oncol 2000; 23: 341-4.
-
(2000)
Am J Clin Oncol
, vol.23
, pp. 341-344
-
-
Mavroudis, D.1
Kourousis, C.2
Androulakis, N.3
-
21
-
-
0031202528
-
Docetaxel in combination with fluorouracil for advanced solid tumors
-
Huntingt
-
Burris HA 3rd. Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Huntingt) 1997; 11: 50-2.
-
(1997)
Oncology
, vol.11
, pp. 50-52
-
-
Burris III, H.A.1
-
22
-
-
0001095836
-
Docetaxel with weekly high-dose 5-FU and lecovorin: A new combination in advanced gastric cancer
-
35th annual meeting: 1079 abstract
-
Constenla M, Lorenzo I, Carrete N, et al. Docetaxel with weekly high-dose 5-FU and lecovorin: a new combination in advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 35th annual meeting: 1079 abstract.
-
(1999)
Proc Am Soc Clin Oncol
-
-
Constenla, M.1
Lorenzo, I.2
Carrete, N.3
-
23
-
-
0011678401
-
Weekly docetaxel and continuous infusion 5-FU in elderly patients with cancer of the stomach and lower esophagus
-
37th annual meeting: 645 abstract
-
Chun HG, Puccio CA, Mittelman A. Weekly docetaxel and continuous infusion 5-FU in elderly patients with cancer of the stomach and lower esophagus. Proc Am Soc Clin Oncol 2001; 37th annual meeting: 645 abstract.
-
(2001)
Proc Am Soc Clin Oncol
-
-
Chun, H.G.1
Puccio, C.A.2
Mittelman, A.3
-
24
-
-
0345723828
-
A phase II study of docetaxel in combination with irinotecan (CPT-11) in locally advanced or metastatic gastric cancer
-
GOTI study group. 37th annual meeting: 2325 abstract
-
Enrech S, Belon J, Mendez M, et al. A phase II study of docetaxel in combination with irinotecan (CPT-11) in locally advanced or metastatic gastric cancer. GOTI study group. Proc Am Soc Clin Oncol 2001; 37th annual meeting: 2325 abstract.
-
(2001)
Proc Am Soc Clin Oncol
-
-
Enrech, S.1
Belon, J.2
Mendez, M.3
-
25
-
-
0005832836
-
Docetaxel-epirubicin as second-line treatment for patients with advanced gastric cancer
-
35th annual meeting: 1062 abstract
-
Andre T, Louvet C, Ychou M, et al. Docetaxel-epirubicin as second-line treatment for patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 35th annual meeting: 1062 abstract.
-
(1999)
Proc Am Soc Clin Oncol
-
-
Andre, T.1
Louvet, C.2
Ychou, M.3
-
26
-
-
0034154069
-
Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)
-
Mar
-
Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000 Mar; 11(3): 301-6.
-
(2000)
Ann Oncol
, vol.11
, Issue.3
, pp. 301-306
-
-
Roth, A.D.1
Maibach, R.2
Martinelli, G.3
-
27
-
-
0035131823
-
Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer
-
Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001; 12: 47-51.
-
(2001)
Ann Oncol
, vol.12
, pp. 47-51
-
-
Ridwelski, K.1
Gebauer, T.2
Fahlke, J.3
-
28
-
-
0003243267
-
Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer. Results of two phase II studies
-
37th annual meeting: 657 abstract
-
Kettner E, Ridwelski K, Keiholz U, et al. Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer. Results of two phase II studies. Proc Am Soc Clin Oncol 2001; 37th annual meeting: 657 abstract.
-
(2001)
Proc Am Soc Clin Oncol
-
-
Kettner, E.1
Ridwelski, K.2
Keiholz, U.3
-
29
-
-
0000432526
-
5FU as protracted continuous iv infusion can be added to full dose taxotere-cisplatin in advanced gastric carcinoma
-
Roth AD, Maibach R, Fazio N, et al. 5FU as protracted continuous iv infusion can be added to full dose taxotere-cisplatin in advanced gastric carcinoma. Eur J Cancer 1999; 35(Suppl 4): 139.
-
(1999)
Eur J Cancer
, vol.35
, Issue.4 SUPPL.
, pp. 139
-
-
Roth, A.D.1
Maibach, R.2
Fazio, N.3
-
30
-
-
0001155743
-
Multinational randomized trial of docetaxel, cisplatin with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma
-
36th annual meeting: 957 abstract
-
Ajani JA, Fodor M, Van Cutsem E, et al. Multinational randomized trial of docetaxel, cisplatin with or without 5-fluorouracil in patients with advanced gastric or GE junction adenocarcinoma. Proc Am Soc Clin Oncol 2000; 36th annual meeting: 957 abstract.
-
(2000)
Proc Am Soc Clin Oncol
-
-
Ajani, J.A.1
Fodor, M.2
Van Cutsem, E.3
-
31
-
-
0345292176
-
Phase I trial of Taxotere, cisplatin, and CPT-11 in advanced solid tumor malignancies
-
37th annual meeting: 2087 abstract
-
Fuchs CS, Lynch TJ, Earle CC, et al. Phase I trial of Taxotere, cisplatin, and CPT-11 in advanced solid tumor malignancies. ProcAm Soc Clin Oncol 2001; 37th annual meeting: 2087 abstract.
-
(2001)
ProcAm Soc Clin Oncol
-
-
Fuchs, C.S.1
Lynch, T.J.2
Earle, C.C.3
-
32
-
-
0345723827
-
Epirubicin, cisplatin, and docetaxel (ECD) for measurable advanced gastric carcinoma. Preliminary data
-
27th meeting: 739 abstract
-
Di Lauro L, Belli F, Del Monte G, Carpano S. Epirubicin, cisplatin, and docetaxel (ECD) for measurable advanced gastric carcinoma. Preliminary data. Proc Eur Soc Med Oncol 2002; 27th meeting: 739 abstract.
-
(2002)
Proc Eur Soc Med Oncol
-
-
Di Lauro, L.1
Belli, F.2
Del Monte, G.3
Carpano, S.4
-
33
-
-
0344429131
-
A phase II multicentric trial of docetaxel (Taxotere), 5-fluorouracil (5-FU) and epirubicin (EPI) in previously untreated advanced gastric cancer: A novel and effective regimen
-
27th meeting: 710 abstract
-
Murad AM, Garcia RF, Vinholes J, et al. A phase II multicentric trial of docetaxel (Taxotere), 5-fluorouracil (5-FU) and epirubicin (EPI) in previously untreated advanced gastric cancer: a novel and effective regimen. Proc Eur Soc Med Oncol 2002; 27th meeting: 710 abstract.
-
(2002)
Proc Eur Soc Med Oncol
-
-
Murad, A.M.1
Garcia, R.F.2
Vinholes, J.3
-
34
-
-
0345292178
-
Docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: Interim analysis results on efficacy and safety in a multicenter randomized phase III study
-
38th annual meeting: 587 abstract
-
Moiseyenko M, Van Cutsem E, Tjulandin S, et al. Docetaxel-cisplatin-5-FU (DCF) versus cisplatin-5-FU (CF) as first line therapy for gastric cancer: interim analysis results on efficacy and safety in a multicenter randomized phase III study. Proc Am Soc Clin Oncol 2002; 38th annual meeting: 587 abstract.
-
(2002)
Proc Am Soc Clin Oncol
-
-
Moiseyenko, M.1
Van Cutsem, E.2
Tjulandin, S.3
-
35
-
-
0344860876
-
TCFW: 5 FU pvi in combination with weekly docetaxel and CDDP in advanced gastric cancer, a phase I-II study: The dose finding step. 'Rete Oncologica Piemontese'
-
38th annual meeting: 2234 abstract
-
Ostellino O, Porcile G, Alabiso O, et al. TCFW: 5 FU pvi in combination with weekly docetaxel and CDDP in advanced gastric cancer, a phase I-II study: the dose finding step. 'Rete Oncologica Piemontese'. Proc Am Soc Clin Oncol 2002; 38th annual meeting: 2234 abstract.
-
(2002)
Proc Am Soc Clin Oncol
-
-
Ostellino, O.1
Porcile, G.2
Alabiso, O.3
-
36
-
-
0345292174
-
Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma: A randomized phase II study
-
38th annual meeting: 647 abstract
-
Patience PC, Kretzschmar A, Vielhaber A, et al. Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma: a randomized phase II study. Proc Am Soc Clin Oncol 2002; 38th annual meeting: 647 abstract.
-
(2002)
Proc Am Soc Clin Oncol
-
-
Patience, P.C.1
Kretzschmar, A.2
Vielhaber, A.3
-
37
-
-
0032921628
-
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial
-
Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80: 269-72.
-
(1999)
Br J Cancer
, vol.80
, pp. 269-272
-
-
Waters, J.S.1
Norman, A.2
Cunningham, D.3
-
38
-
-
0028016155
-
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)
-
Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-16.
-
(1994)
Ann Oncol
, vol.5
, pp. 609-616
-
-
Findlay, M.1
Cunningham, D.2
Norman, A.3
-
40
-
-
0031022803
-
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer
-
Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7.
-
(1997)
J Clin Oncol
, vol.15
, pp. 261-267
-
-
Webb, A.1
Cunningham, D.2
Scarffe, J.H.3
-
41
-
-
0033909505
-
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group
-
Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-57.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2648-2657
-
-
Vanhoefer, U.1
Rougier, P.2
Wilke, H.3
-
42
-
-
0026548710
-
FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer
-
Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-8.
-
(1992)
J Clin Oncol
, vol.10
, pp. 541-548
-
-
Kelsen, D.1
Atiq, O.T.2
Saltz, L.3
-
43
-
-
4243806612
-
PELF is more active than FAMTX in Metastatic Gastric Carcinoma (MGC)
-
37th annual meeting: 501 abstract
-
Cocconi G, Carlini P, Gamboni A, et al. PELF is more active than FAMTX in Metastatic Gastric Carcinoma (MGC). Proc Am Soc Clin Oncol 2001; 37th annual meeting: 501 abstract.
-
(2001)
Proc Am Soc Clin Oncol
-
-
Cocconi, G.1
Carlini, P.2
Gamboni, A.3
-
44
-
-
0022504529
-
Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy
-
Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986; 46: 3876-85.
-
(1986)
Cancer Res
, vol.46
, pp. 3876-3885
-
-
Day, R.S.1
-
45
-
-
0033624853
-
Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms
-
Fizazi K, Zelek L. Is one cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann Oncol 2000; 11(2): 133-49.
-
(2000)
Ann Oncol
, vol.11
, Issue.2
, pp. 133-149
-
-
Fizazi, K.1
Zelek, L.2
|